No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection

Basma Abdi, Thuy Nguyen, Sophie Brouillet, Nathalie Desire, Sophie Sayon, Marc Wirden, Aude Jary, Guillaume Achaz, Lambert Assoumou, Romain Palich, et al.

► To cite this version:

Basma Abdi, Thuy Nguyen, Sophie Brouillet, Nathalie Desire, Sophie Sayon, et al.. No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection. *AIDS. Official journal of the international AIDS Society*, 2020, 34 (12), pp.1745-1753. 10.1097/QAD.0000000000002629 . hal-03182806

HAL Id: hal-03182806

<https://hal.sorbonne-universite.fr/hal-03182806>

Submitted on 26 Mar 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **No HIV-1 Molecular Evolution On Long Term Antiretroviral Therapy Initiated During**
2 **Primary HIV-1 Infection.**

3

4 **Running head: Viral Diversity In Primary HIV infection**

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

Authors: Basma ABDI¹, Thuy NGUYEN¹, Sophie BROUILLET², Nathalie DESIRE¹, Sophie SAYON¹, Marc WIRDEN¹, Aude JARY¹, Guillaume ACHAZ², Lambert ASSOUMOU³, Romain PALICH⁴, Anne SIMON⁵, Roland TUBIANA⁴, Marc-Antoine VALANTIN⁴, Christine KATLAMA⁴, Vincent CALVEZ¹, Anne-Geneviève MARCELIN¹, Cathia SOULIE¹

¹Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de virologie, Paris, France; ²Institut de Systématique, Evolution, Biodiversité (ISYEB), Muséum national d'Histoire naturelle, CNRS Sorbonne Université, Paris, France; ³Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France; ⁴ Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP UMRS 1136), AP-HP, Hôpital Pitié Salpêtrière, Service des Maladies Infectieuses, Paris, France ⁵Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, (IPLESP UMRS 1136), AP-HP, Hôpital Pitié Salpêtrière, Service de Médecine Interne, Paris, France.

Corresponding author : Dr Basma ABDI, Laboratoire de Virologie-CERVI, Hôpital Pitié Salpêtrière 45-83 Bd de l'hôpital 75013 Paris, France. Phone: 33 1 42 17 58 42. Fax: 33 1 42 17 74 11. Email: basma.abdi@aphp.fr

Word number: 2977

Introduction

Primary-HIV1 (PHI) infection is the initial phase of infection. It represents the time when the virus is first disseminating throughout the body and induces host immune responses [1–3]. The HIV reservoir is established very rapidly during this stage, due to the provirus integrated into the genome of cells that enables the persistence and the establishment of a latent reservoir which remains the major obstacle to eliminate the virus [4].

Several studies have demonstrated that early antiretroviral therapy (ART) initiation can be particularly effective for long term control of HIV-1 replication and it is associated with a faster decay of the latent reservoir, a restriction of its size and an optimal immune restoration [5–7].

Whilst, large clinical trials demonstrated that the benefits of earlier treatment mentioned above were limited at these specific criteria because treatment interruption is usually followed by rapid viral rebound, CD4+ T-cells loss and increased risk of morbidity and mortality [8–11].

In case of clinical effective ART, residual viremia has been evidenced and could be caused by ongoing low-level virus replication or by release of viral particles and/or viral genome from infected cells [12]. Effectively, it has been suggested that persistent virus replication at low levels may be an important contributor to the maintenance of the reservoir particularly in

lymphoid tissue sanctuary sites [13]. However, other studies suggest that there is no evidence of HIV replication on ART and the lack of genetic structure of HIV populations during ART argues against ongoing residual replication [13–15].

A better understanding of changes in HIV-1 population genetics with ART is necessary to conclude between these two hypotheses and then for designing and optimizing new eradication strategies. PHI is a particular situation where the low diversity of the transmitted viruses has been described and thus investigating patients who started ART during the earliest stages of their HIV infection provides an opportunity to detect evidence of viral evolution.

We aim to study HIV-1 diversity in patients diagnosed with a primary HIV-1 infection, treated at the time of acute infection and with strict effective long term suppressive ART.

Materials and methods

We analyzed HIV-1 genetic variation and divergence of viral populations over time in plasma samples (RNA) before ART initiation and in blood cell samples (DNA) during 5 years of viral suppression on ART.

Patients

We retrospectively studied 20 patients diagnosed during PHI in the Departments of Infectious Diseases and Internal Medicine at Pitié-Salpêtrière Hospital (Paris, France). PHI was defined

as detectable plasma HIV-RNA and an incomplete HIV-1 Western blot, irrespective of the ELISA result (positive or negative) and p24 antigenaemia (positive or negative).

Patients received antiretroviral therapy very early after infection and were identified with a strict viral suppression (HIV plasma RNA < 20 copies/mL without any blips) for at least 5 years afterward under ART. Analyses were performed retrospectively on frozen samples of whole blood taken during 5 years of standard follow-up.

Ethical considerations

This retrospective study was conducted in accordance with Good Clinical Practices and the ethical principles of the Helsinki declaration, and following ANRS standard practices for clinical research. Patients had written consent that the remnant of their samples could be used for research purpose.

Total HIV-DNA quantification

Cell-associated HIV-1 DNA was quantified by ultrasensitive real-time PCR (Generic HIV-DNA assay, Biocentric, Bandol, France) as previously described [16].

HIV-RNA quantification and Ultra-Sensitive Viral Load

Plasma Viral Load (pVL) was quantified using the Cobas AmpliPrep/CobasTaqMan HIV-1 assay (Roche Diagnostics; lower detection limit of 20 copies/mL). Ultra-sensitive viral load (USVL) in the range of 1–20 copies/mL was indicated qualitatively (presence or absence of detectable signal).

101

102 **Ultra-Deep-Sequencing**

103 **RNA and DNA extraction, amplification and ultra-deep sequencing**

104 HIV RNA was extracted from 1 ml of plasma using easyMAG® (bioMérieux Clinical
105 Diagnostics, France) and HIV DNA was extracted from 400 mL of PBMC using the MagnaPure
106 LC DNA Isolation Kit from Roche according to the manufacturer's instructions.

107 UDS was performed using Illumina Miseq technology (Illumina, San Diego, CA, USA). We
108 deep sequenced 2 fragments RT1 and RT2 of reverse transcriptase (RT) gene (413pb: 2618-
109 3031 and 446pb: 2877-3323 relative to HXB2 genome, respectively) and C2V3 region of gp
110 120 gene (367pb: 7011-7378 relative to HXB2 genome). Details of primers and PCR
111 procedures used for UDS are described in Supplemental Data.

112 Three samples were sequenced per patient: one RNA-HIV: plasma at baseline prior ART
113 initiation, two HIV DNA associated with peripheral blood cells under effective ART: first point
114 of pVL < 20 copies/mL and 5 years follow-up period. Library construction from purified PCR
115 products (RT1, RT2 and C2V3 amplicons) and 2x300 bp Illumina Miseq paired-end sequencing
116 were performed at the Genotyping and Sequencing Platform, ICM Brain and Spine Institute
117 (Paris, France). Sequences were demultiplexed automatically on the MiSeq platform as part of
118 the data processing steps and two paired fastq files were generated for each sample representing
119 the two paired-end reads.

120

121 **HIV drug resistance testing by UDS**

To identify Drug Resistance Associated Mutations (DRAMs), the sequence reads were analyzed with IDNS[®] © SmartGene 2019 (Advanced sequencing platform) and resistance (Cutoff detection of minority resistant variant of UDS sequences =2%) was interpreted using the latest ANRS resistance algorithm (<http://www.hivfrenchresistance.org>). Variants present in more than 20% of the quasispecies were considered to be majority resistant variants and variants present at a proportion between 2% and 20% were considered to be minority variants.

Phylogenetic analysis

We used Geneious research software (version 11) for phylogenetic analysis [17]. The paired-end reads are merged and quality-filtered to remove noise. Alignment is performed using a target-specific profile and a consensus is produced based on a user-selected ambiguity threshold. We used PhyML for maximum-likelihood (ML) phylogenetic reconstruction (Generalized time-reversible model (GTR)). The best subtree pruning and regrafting (SPR) and the nearest neighbor interchange (NNI) heuristic options were selected. The reliability of tree topologies was assessed by bootstrapping using 1000 replications (values $\geq 70\%$ were considered significant). ML trees were rooted on an outgroup: HIV subtype B consensus (HxB2: K03455; www.hiv.lanl.gov). Tree figures were viewed and modified with FigTree software (<http://tree.bio.ed.ac.uk/software/figtree/>).

Diversity analysis

To look for evidence of ongoing viral replication during ART, HIV populations in samples taken at baseline were compared with the populations present during and after long-term ART in RT and gp120 genes. Phylogenetic trees were constructed for each patient with sequences

obtained from plasma at baseline prior ART initiation and HIV DNA associated with peripheral blood cells under effective ART (first point of pVL < 20 copies/mL and 5 years follow-up period). Population genetic diversity was calculated as average pairwise difference (APD) using MEGAX (<http://www.megasoftware.net>) [18].

Viral evolution was established when temporal structure on ML maximum-likelihood phylogenetic trees and significant change over time of HIV-1 genetic diversity (APD) were observed.

HIV-1 Tropism

HIV-1 co-receptor usage was predicted by a genotypic method that used the Geno2phenoreceptor rule (<https://coreceptor.geno2pheno.org/>) and according to ANRS rules (<http://www.hivfrenchresistance.org/hiv-tropism.html>).

Statistical analysis

All reported values are medians with interquartile range (IQR) for continuous variables and frequencies and percentages for categorical variables. Changes in cell associated HIV-DNA and CD4 cell count were compared between baseline and month 60 using paired Wilcoxon test and the Mann-Whitney test was for comparison between participants with DRAMs dynamics and those with not. Univariable model was used to identify factors associated with DRAMs: age, sex, transmission group, duration of ART, baseline CD4 and CD8 cell counts, CD4/CD8 ratio, nadir CD4 cell count, time since HIV diagnosis, duration of suppressed viraemia, time to ART initiation, time to undetectable viral load under ART, duration of infection, pre-ART pVL,

peak of pVL, baseline HIV cell-associated DNA, HIV-1 subtype, CD4 cell count and HIV cell-associated DNA during follow up.

All reported P values are two-tailed, with significance set at 0.05. Analyses were performed with SPSS statistics version 23.0 for Windows.

Results

Patients' characteristics at time of PHI

Twenty patients with strict viral suppression (HIV viral load <20 copies/mL without any blips) were included in the study with a median age of 47 years (IQR 34-53). Eighteen (90%) were male. Nine of the patients (45%) and 11/20 (55%) were diagnosed at Fiebig stages III and IV, respectively. Fifteen patients (75%) were symptomatic at time of PHI. Time to ART initiation, time to undetectable viral load under ART and duration of infection was in median 5 days (IQR 1-12), 95 days (IQR 40-119) and 6 years (IQR 6-7), respectively. Of the 20 patients, 12 (60%) were infected with the clade B virus. Main characteristics of patients are summarized in table 1.

Evolution of immunological and virological parameters

Evolution of immunological and virological parameters is presented in figure 1. A median of 10 longitudinal plasma HIV-1 RNA was evaluated per patient (197 samples in total). The median HIV-RNA viral load (VL) at time of PHI was 5.7 log₁₀ copies/mL (IQR: 4.94-6.26) and decreased quickly with all patients reaching VL < 20 copies/mL in a median of 95 days (IQR:

40 -119) of ART initiation. Ultrasensitive VL (presence of detectable signal between 1-20 copies/mL) was found at least once during the 5 years follow-up in 13/20 patients (65%).

The total cell-associated HIV-1 DNA level was assayed for a median of 8 longitudinal blood samples per participant (158 samples in total). The median HIV-1 DNA load at PHI and over 5 years of follow up was 3.24 log₁₀ copies/10⁶ cells (IQR: 2.72 to 3.49) and 1.60 log₁₀ copies/10⁶ cells (IQR:1.60), respectively. The analysis revealed a global and significant decrease in total HIV-1 DNA during follow up period (p= 0.02). The total cell-associated HIV-1 DNA load was not detectable (<40 copies/10⁶ cells) for 14 (70%) patients at the end of follow up.

Resistance analysis and tropism

At baseline, DRAMs were detected in RT gene in 3 (15%) patients with 2 majority resistant variants: 2 K103N (98%) and 1 minority resistant variant Y188H (2%). Regarding longitudinal dynamics of NRTI and NNRTI DRAMs, DRAMs at baseline were compared with archived DRAMs during follow up period (table 2). New DRAMs were detected in 9 patients (45%) despite fully sustained suppression of HIV-RNA in plasma with new archived DRAMs in 4/20 (25%) patients at the first point of pVL < 20 copies/mL: patients 4, 5, 16 and 17. Seven (35%) individuals had at least 1 emerging DRAM in peripheral blood cells after 5 years of follow up (most of them were detected at less than 10%): patients 3, 4, 9, 10, 11, 12 and 16 (table 2). Fifty-five percent (5/9) of patients who showed emergence of DRAMs had one residual viremia at least once during follow up. The comparison between the characteristics of patients with new archived DRAMs and those without revealing that only transmission group is associated with the dynamics of archived DRAMs. Effectively, all patients who had variants with new DRAMs were MSM (P= 0.02).

Five patients (25%) had at least one G-to-A mutation resistance associated mutation: patient 4: D67N (9.9%) and M184I (2.7%); patient 5: M230I (98.9%); patient 10: M184I (2.3%); patient 12: D67N (7.2%) and patient 16: D67N (4.4%), M184I (98%) and M230I (100%) (table 2).

Fifteen patients (75%) harbored a CCR5-tropic virus. The genotypic prediction of C2V3 co-receptor tropism did not vary over time in all patients.

Search of potential HIV genetic evolution - Phylogenetic studies

Phylogenetic analyses were processed in the 20 individuals, in RT and gp120 gene. Analysis showed that in all patients, sequences were intermingled: in each patient, sequences obtained from three different time points were highly homogenous. Tree topologies showed an absence of segregation between sequences in HIV-1 RNA at baseline prior to ART and in cell-associated HIV-DNA during 5 years of ART (figure 2).

The average nucleotide pairwise distance (APD) was estimated between the reads obtained from each time point. In the first sample (in HIV-RNA at baseline prior to ART), the median of APD was 1% (IQR: 1-1), 1% (IQR: 1-1) and 2% (IQR: 1-2) in RT1 fragment, RT2 fragment and gp120 gene respectively. In the second sample (in cell associated HIV-DNA; first time point of plasma VL < 20 copies/mL) the median of APD was 1% (IQR: 1-2), 1% (IQR: 1-1) and 2% (IQR: 1-3.75) respectively in RT1 fragment, RT2 fragment and gp120. In the third sample (in cell associated HIV-DNA after 5 years of follow up), the median of APD was 1% (IQR: 1-2), 1% (IQR: 1-1) and 2% (IQR: 1-2) in RT1 fragment, RT2 fragment and gp120 gene respectively. This comparison of the APD in sequences obtained from samples taken at different times showed the absence of arguments of significant viral diversity evolution between primary infection and during the following 5 years.

Discussion

To our knowledge, it is the first study to report quantitative and qualitative analysis by UDS of HIV-1 reservoir in twenty patients diagnosed in the acute phase of infection, treated very early and had strict effective long term suppressive ART (during at least 5 years of follow up). There was a significant decay of HIV-RNA and cell-associated HIV DNA in our study in participants who started ART during the first month of their infection. Phylogenetic analysis showed the absence of genetic divergence and diversity in the RT and gp120 genes over time. However, despite sustained virological control under ART, some minor variations (emergence or disappearance) of DRAMS were evidenced associated or not with the current antiretroviral treatment.

Our results are in line with a number of studies showing the faster decrease of HIV DNA in patients starting ART during acute HIV-1 [19–21] infection . However, some clinical trials evidenced a viral rebound after prolonged virologic suppression with no difference in virological and immunological parameters between immediate and delayed treatment in the vast majority of cases [8–11,22].

In this study, 15% of NNRTI DRAMs (2 K103N and 1 Y188H) were revealed at the time of primary HIV infection. This prevalence is similar to the latest data (2014-2016) from the French cohort of primary infections showing that 18.6% of patients had DRAMS at baseline with the highest level of resistance to the NNRTI class (13.4%) [23].

Concerning longitudinal dynamics of minority variants, new DRAMS, not detected at baseline, appeared during follow-up in some patients treated early during the acute phase of HIV-1 infection despite a fully controlled viremia < 20 cp/mL and absence of detected residual viremia in 45% (4/9) of cases. This finding is consistent with the assessments carried out by

Gantner et al; they used the UDS technique to assess the longitudinal dynamics of viral resistant quasispecies archived in blood and demonstrated that, despite virological control, the diversity of the quasispecies continued to evolve [24]. This could be the result of persistence of a residual viremia below the limit of standard quantification in some patients. Other researchers suggested that the new variants have most probably been selected directly in the blood compartment or other reservoirs because of insufficient drug penetration [24–26]. In addition, some of these new DRAMs in blood cells were G-to-A mutations implicating APOBEC3 editing, a cellular enzyme action and not viral replication [27].

The results of phylogenetic analysis, as well phylogenetic tree and average pairwise distance, suggested the absence of genetic changes in archived HIV-1 DNA in our patients treated during the acute phase of infection with effective ART. Our findings support the majority of the studies reporting the lack of viral evolution during suppressive ART in chronically HIV infected adults, as well as in children treated shortly after birth when viral diversity is low [14,15,28]. This absence of sequence divergence is indicative of long-lived cells infected and argues against viral replication being the major source of persistent viremia [14,15,28–30]. On another side, Lorenzo *et al.* reported that anatomical sanctuary sites such as the lymph nodes can allow residual viral replication on ART, contributing to the maintenance of the HIV reservoir [31]. These findings were strongly criticized by Kearney *et al.* who re-analyzed data and reported limits of data according to the low number of samples, the short time of the survey and absence of evidence of viral evolution using more complex analyses [29]. There are several reasons to explain controversy results such as differences in study populations (children treated shortly after birth, adults with chronic infection, patients diagnosed in acute phase of infection), in sampling (plasma, cell associated HIV-DNA, lymph nodes), in sequencing (Sanger sequencing, Single Genome Sequencing, UDS: 454 Roche and Illumina technology) and in analysis

(phylogenetic analysis, measure of the APD, test of panmixia and others mathematics methods...) [13–15,28–30,32].

Phylogenetic analysis allowed the comparison of the integrality of sequences which is more informative about viral diversity than the study of few resistance positions in the RT sequence. Then, the impact of rare resistant variants could be diluted and doesn't impact phylogenetic analysis and could explain the apparent discrepancy between the DRAMs variation and the stability in phylogenetic analysis in our study.

Conclusion

In conclusion, this study is the first to use the UDS technique to assess the longitudinal dynamics of viral populations in plasma prior to ART and in archived blood cells in sustained ART in patients diagnosed with a primary HIV-1 infection and treated very early. Despite a slight variation of minority resistance-associated mutation variants, there was no clear evidence of viral evolution during a prolonged period of time. Our results underlined that ART initiation during PHI is fundamental to positively impact quantitative and qualitative biological parameters related to the HIV-1 reservoir in order to reduce its size and to control the viral diversity in the perspective to design of HIV-1 cure strategies.

ACKNOWLEDGEMENTS

The Genotyping and Sequencing Platform, ICM Brain and Spine Institute (Paris, France).

TRANSPARENCY DECLARATION

305 All other authors: none to declare.

306

307 **Acknowledgements**

308 B.A., C.S., A.G.M., V.C. designed the study; R.P., A.S., R.T., M.A.V., C.K provided medical
309 care to the participants and collected clinical data; B.A., T.N., S.S collected biological data
310 and performed experiments; B.A., T.N., N.D., S.B., G.A., L.A., analyzed results; B.A., C.S.
311 wrote the paper; All authors reviewed and accepted the final version of the manuscript.

312

313 **REFERENCES**

314 1 Kassutto S, Rosenberg ES. **Primary HIV Type 1 Infection.** *Clin Infect Dis* 2004;
315 **38**:1447–1453.

316 2 Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, *et al.* **Antiretroviral**
317 **Therapy in Acute and Recent HIV Infection: A Prospective Multicenter Stratified**
318 **Trial of Intentionally Interrupted Treatment.** *AIDS (London, England)* 2009; **23**:1987.

319 3 Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, *et al.*
320 **Dynamics of HIV viremia and antibody seroconversion in plasma donors:**
321 **implications for diagnosis and staging of primary HIV infection.** *AIDS* 2003;
322 **17**:1871–1879.

323 4 Bacchus C, Cheret A, Avettand-Fenoël V, Nembot G, Mélard A, Blanc C, *et al.* **A Single**
324 **HIV-1 Cluster and a Skewed Immune Homeostasis Drive the Early Spread of HIV**
325 **among Resting CD4+ Cell Subsets within One Month Post-Infection.** *PLoS One* 2013;
326 **8.** doi:10.1371/journal.pone.0064219

- 327 5 Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, *et al.* **Effect of**
328 **treatment, during primary infection, on establishment and clearance of cellular**
329 **reservoirs of HIV-1.** *J Infect Dis* 2005; **191**:1410–1418.
- 330 6 Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, *et al.*
331 **Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to**
332 **achieving both low HIV reservoirs and normal T cell counts.** *J Antimicrob Chemother*
333 2013; **68**:1169–1178.
- 334 7 Schmid A, Gianella S, von Wyl V, Metzner KJ, Scherrer AU, Niederöst B, *et al.*
335 **Profound depletion of HIV-1 transcription in patients initiating antiretroviral**
336 **therapy during acute infection.** *PLoS ONE* 2010; **5**:e13310.
- 337 8 Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, *et al.* **Plasma**
338 **HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in**
339 **Primary and Chronic HIV Infection.** *PLoS One* 2012; **7**.
340 doi:10.1371/journal.pone.0043754
- 341 9 Grijzen ML, Steingrover R, Wit FWNM, Jurriaans S, Verbon A, Brinkman K, *et al.* **No**
342 **Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV**
343 **Infection: The Randomized Primo-SHM Trial.** *PLoS Med* 2012; **9**.
344 doi:10.1371/journal.pmed.1001196
- 345 10 Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher AD, *et al.* **The**
346 **impact of transient combination antiretroviral treatment in early HIV infection on**
347 **viral suppression and immunologic response in later treatment.** *AIDS* 2016; **30**:879–
348 888.

- 349 11 Fidler S, Olson AD, Bucher HC, Fox J, Thornhill J, Morrison C, *et al.* **Virological Blips**
350 **and Predictors of Post Treatment Viral Control After Stopping ART Started in**
351 **Primary HIV Infection.** *JAIDS Journal of Acquired Immune Deficiency Syndromes*
352 2017; **74**:126–133.
- 353 12 Chaillon A, Gianella S, Lada SM, Perez-Santiago J, Jordan P, Ignacio C, *et al.* **Size,**
354 **Composition, and Evolution of HIV DNA Populations during Early Antiretroviral**
355 **Therapy and Intensification with Maraviroc.** *J Virol* 2018; **92**. doi:10.1128/JVI.01589-
356 17
- 357 13 Lorenzo-Redondo R, Fryer HR, Bedford T, Kim E-Y, Archer J, Pond SLK, *et al.*
358 **Persistent HIV-1 replication maintains the tissue reservoir during therapy.** *Nature*
359 2016; **530**:51–56.
- 360 14 van Zyl G, Bale MJ, Kearney MF. **HIV evolution and diversity in ART-treated**
361 **patients.** *Retrovirology* 2018; **15**:14.
- 362 15 Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, O’Shea A, *et al.* **Lack of**
363 **Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy.**
364 *PLoS Pathog* 2014; **10**. doi:10.1371/journal.ppat.1004010
- 365 16 Avettand-Fènoël V, Chaix M-L, Blanche S, Burgard M, Floch C, Toure K, *et al.* **LTR**
366 **real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in**
367 **infants born to seropositive mothers treated in HAART area (ANRS CO 01).** *J Med*
368 *Virol* 2009; **81**:217–223.
- 369 17 Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, *et al.* **Geneious**
370 **Basic: An integrated and extendable desktop software platform for the organization**
371 **and analysis of sequence data.** *Bioinformatics* 2012; **28**:1647–1649.

- 372 18 Tamura K, Nei M. **Estimation of the number of nucleotide substitutions in the control**
373 **region of mitochondrial DNA in humans and chimpanzees.** *Mol Biol Evol* 1993;
374 **10:512–526.**
- 375 19 Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, Mélard A, Nembot G, Blanc C, *et al.*
376 **Combined ART started during acute HIV infection protects central memory CD4+**
377 **T cells and can induce remission.** *J Antimicrob Chemother* 2015; **70**:2108–2120.
- 378 20 Chéret A, Durier C, Mélard A, Ploquin M, Heitzmann J, Lécuroux C, *et al.* **Impact of**
379 **early cART on HIV blood and semen compartments at the time of primary infection.**
380 *PLoS ONE* 2017; **12**:e0180191.
- 381 21 Leite TF, Delatorre E, Côrtes FH, Ferreira ACG, Cardoso SW, Grinsztejn B, *et al.*
382 **Reduction of HIV-1 Reservoir Size and Diversity After 1 Year of cART Among**
383 **Brazilian Individuals Starting Treatment During Early Stages of Acute Infection.**
384 *Front Microbiol* 2019; **10**. doi:10.3389/fmicb.2019.00145
- 385 22 Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K, *et al.* **The effect of**
386 **antiretroviral treatment of different durations in primary HIV infection.** *AIDS* 2008;
387 **22:2441–2450.**
- 388 23 Visseaux B, Assoumou L, Mahjoub N, Grude M, Tra baud M-A, Raymond S, *et al.*
389 **Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable**
390 **resistance, but higher diversity, clustering and virulence?** *J Antimicrob Chemother*
391 2020; **75**:183–193.
- 392 24 Gantner P, Morand-Joubert L, Sueur C, Raffi F, Fagard C, Lascoux-Combe C, *et al.* **Drug**
393 **resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in**

394 **blood cells of heavily pretreated patients who achieved sustained virological**
395 **suppression.** *J Antimicrob Chemother* 2016; **71**:751–761.

396 25 Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, *et al.* **Low-level**
397 **viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.**
398 *Proc Natl Acad Sci USA* 2008; **105**:3879–3884.

399 26 Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, *et al.* **Plasma HIV-1**
400 **RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving**
401 **highly active antiretroviral therapy.** *Clin Infect Dis* 2012; **54**:724–732.

402 27 Fourati S, Lambert-Niclot S, Soulie C, Wirden M, Malet I, Valantin MA, *et al.*
403 **Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse**
404 **anatomical compartments.** *AIDS* 2014; **28**:487–491.

405 28 Van Zyl GU, Katusiime MG, Wiegand A, McManus WR, Bale MJ, Halvas EK, *et al.* **No**
406 **evidence of HIV replication in children on antiretroviral therapy.** *J Clin Invest* 2017;
407 **127**:3827–3834.

408 29 Kearney MF, Wiegand A, Shao W, McManus WR, Bale MJ, Luke B, *et al.* **Ongoing HIV**
409 **Replication During ART Reconsidered.** *Open Forum Infect Dis* 2017; **4**.
410 doi:10.1093/ofid/ofx173

411 30 Kearney MF, Wiegand A, Shao W, Coffin JM, Mellors JW, Lederman M, *et al.* **Origin of**
412 **Rebound Plasma HIV Includes Cells with Identical Proviruses That Are**
413 **Transcriptionally Active before Stopping of Antiretroviral Therapy.** *J Virol* 2016;
414 **90**:1369–1376.

- 415 31 Lorenzo-Redondo R, Fryer HR, Bedford T, Kim E-Y, Archer J, Pond SLK, *et al.*
416 **Persistent HIV-1 replication maintains the tissue reservoir during therapy.** *Nature*
417 2016; **530**:51–56.
- 418 32 Achaz G, Palmer S, Kearney M, Maldarelli F, Mellors JW, Coffin JM, *et al.* **A robust**
419 **measure of HIV-1 population turnover within chronically infected individuals.** *Mol*
420 *Biol Evol* 2004; **21**:1902–1912.
- 421

Characteristics	Total= 20
Age (years), median (IQR)	47 (34 - 53)
Sex- n (%)	
-Male	18 (90 %)
-Female	2 (10%)
Origin- n (%)	
-Caucasian	19 (95%)
-Others	1 (5%)
Transmission group- n (%)	
-Men who have Sex with Men	15 (75%)
-Heterosexual	5 (25%)
Symptomatic PHI- n (%)	15 (75%)
HLA B57*01- n (%)	
Negative	10 (50%)
ND	10 (50%)
Fiebig stage	
III	9 (45%)
IV	11 (55%)
HIV-1 RNA Zenith (log ₁₀ copies/mL), median (IQR)	5.82 (4.94-6.26)
HIV-1 RNA (log ₁₀ copies/mL), median (IQR)	5.7 (4.94-6.26)
HIV DNA (log ₁₀ copies/10 ⁶ cells), median (IQR)	3.24 (2.72-3.49)
CD4 nadir cell count (cells/mm ³), median (IQR)	417 (325-522)
CD4 cell count (cells/ mm ³), median (IQR)	483 (325-566)
Duration of infection (years), median (IQR)	6 (6-7)
Time from diagnosis to ART initiation (days), median (IQR)	5 (1-12)
Time to undetectable viral load (days), median (IQR)	95 (40 -119)
ART regimen n (%)	
-2 NRTI+2 PI	8 (40%)
-2 NRTI + 1 INI	8 (40%)
-2 NRTI + 1 NNRTI	2 (10%)
-2 NRTI+2 PI+MVC	1 (5%)
-2 NRTI + MVC	1 (5%)

Table 1 : Patients' characteristics at the time of primary infection

PHI=primary HIV-1 infection; ND: Not Determined; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI= non-nucleoside reverse transcriptase inhibitor; PI= protease inhibitor; MVC=maraviroc;

Patient	Time point	Ongoing ART	NRTI DRAMs (% quasiespecies)	NNRTI DRAMs (% quasiespecies)
3	RNA	TDF/FTC/DRV/RTV		Y188H (2.0%)
	DNA*	TDF/FTC/DTG		
4	RNA	ABC/3TC/RAL		K103N (5,5%)
	DNA*	TDF/FTC/DTG		
5	RNA	ABC/3TC/RAL		K103N (5,5%)
	DNA*	TDF/FTC/DTG		
9	RNA	ABC/3TC/RAL		K103N (5,5%)
	DNA*	TDF/FTC/DTG		
10	RNA	ABC/3TC/RAL		K103N (5,5%)
	DNA*	TDF/FTC/DTG		
11	RNA	ABC/3TC/RAL		K103N (5,5%)
	DNA*	TDF/FTC/DTG		
12	RNA	ABC/3TC/RAL		K103N (5,5%)
	DNA*	TDF/FTC/DTG		
16	RNA	ABC/3TC/RAL		K103N (5,5%)
	DNA*	TDF/FTC/DTG		
17	RNA	ABC/3TC/RAL		K103N (5,5%)
	DNA*	TDF/FTC/DTG		

Table 1 : UDS evolution of archived Drug Resistance Associated Mutations in plasma (RNA) at baseline and cell-associated HIV-1 DNA (DNA) under effective antiretroviral

Therapy: results in % (mutation frequency among all reads); ; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI= non-nucleoside reverse transcriptase inhibitor; 3TC:

lamivudine; ABC: abacavir; TDF: tenofovir disoproxil fumarate; FTC: emtricitabine; RPV:

rilpivirine; EFV: efavirenz; DRV/RTV: darunavir/ritonavir; RAL: raltegravir; DTG:

dolutegravir, EVG: elvitégravir;; MVC, maraviroc; COB:cobicistat

DNA*: first point of plasma viral load < 20 copies/mL, DNA**: 5 years of follow-up period

Underlined: mutations associated with prescribed treatment; Italic: mutations not related with prescribed treatment; Bold: G-to-A mutations; Bold and Underlined: patients with at least 1 residual viremia during follow up.

Figure 1: Median of longitudinal plasma HIV-1 RNA, cell associated HIV-1 DNA levels and CD4 cells count in 20 patients: All available samples for 5 years in 20 patients are displayed; D0= Day with confirmed diagnosis of primary HIV-1 infection; M=Month; HIV-1 RNA (Log₁₀ copies/mL); HIV-1 DNA (Log₁₀ copies/10⁶ cells); CD4 cells count (cells/mm³)

Figure 1 : Example of phylogenetic tree for patient 18 constructed from HIV-RNA at baseline prior ART initiation and HIV-DNA associated with peripheral blood sequences: We used PhyML for maximum-likelihood (ML) phylogenetic reconstruction (Generalised time-reverse model (GTR)); ML tree was rooted on an outgroup: HIV subtype B consensus (HxB2: K03455); phylogenetic tree showing intermingled sequences in RT gene.

Supplemental Data

We deep sequenced RT gene into 2 fragments: RT1 (413pb), RT2 (446pb) and gp120 gene (367pb). These genes were amplified using two rounds of PCR amplification.

Details of primers used for amplification are listed in table 1.

PCR1 Forward (for) and PCR1 Reverse (rev) for PCR round one, and PCR 2 for and PCR2 rev for PCR round 2 (nested PCR). To amplify RT1 and RT2 fragments, the following thermocycler parameters were used for PCR1: 50 °C for 30 minutes (mn), 94 °C for 7 mn, 94 °C for 10 seconds (s), 55 °C for 30s, 68 °C for 1 mn, 35 cycles of steps 3–5 and 68 °C for 7 mn. We used a touchdown PCR for round 2 with the following parameters: 98 °C for 1 mn, 3cycles (98°C for 10s; 66-64 °C for 30s; 72°C for 15s), 3cycles (98°C for 10s; 64-62 °C for 30s; 72°C for 15s), 3cycles (98°C for 10s; 62-60 °C for 30s; 72°C for 15s), 30 cycles (98°C for 10s; 60 °C for 30s; 72°C for 15s), and 72 °C for 7 mn.

To amplify ENV C2V3 region, the following thermocycler parameters were used for PCR1: 50 °C for 30 minutes (mn), 94 °C for 7 mn, 94 °C for 10 seconds (s), 53 °C for 30s,

68 °C for 1 mn, 35 cycles of steps 3–5 and 68 °C for 7 mn. Parameters used for PCR2 were:

98 °C for 1 mn, 98°C for 10s, 60 °C for 30s; 72°C for 15s, 40 cycles of steps 2-4 and 72 °C for 7 mn.

Primer Name	Primer Sequence (5'-3' orientation)
RT1-PCR1-for	TAGTCCTATTGARACTGTACCAGT
RT1- PCR1-rev	ATCCTACATACAARTCATCCATG
RT1- PCR2-for	ATGGCCATTGACAGAAGAAA
RT1- PCR2-rev	TGGAATATTGCTGGTGATCC
RT2- PCR1-for	GGGARGTYAATTAGGAATACC
RT2- PCR1-rev	AGTCTTTTGATGGGTCATAATA
RT2- PCR2-for	GATGTGGGkGATGCATATTT
RT2- PCR2-rev	CTGTATGTCATTGACAGTCCAG
V3- PCR1-for	CAG TAC AAT GTA CAC ATG G
V3- PCR1-rev	ATG GGA GGG GCA TAC ATT G
V3- PCR2-for	TTACAGTAGAAAAAT TCC CCT C
V3- PCR2-rev	AAT GGC AGTCTA GCAGAA G

Table 1 : Primers used for Ultra Deep Sequencing

for=forward; rev=reverse